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Abstract
Background: Increasing rates of AQP4-seropositive neuromyelitis optica spectrum disorder (NMOSD) have been
reported in late-onset patients (LONMOSD). However, the full range of clinical differences between early-onset and
late-onset variants remain unclear. We describe the clinical features and outcomes of AQP4-seropositive LONMOSD
patients in a Chinese population.
Methods: This was a retrospective analysis of medical records in a cohort study of AQP4-seropositive NMOSD patients
with early-onset (≤49 years) and late-onset (≥50 years) variants between January 2006 and February 2014. Demographic,
clinical, neuroimaging and cerebrospinal fluid (CSF) findings and prognosis data were analyzed.
Results: We identified thirty AQP4-seropositive LONMOSD patients (86.7 % women). The median age at onset
was 57.5 years (range 50–70). There were similar onset frequencies between optic neuritis (ON) and longitudinally
extensive transverse myelitis (LETM). Longer interval between (first) ON and LETM (median 13 vs. 4 months; p < 0.05),
time from first symptoms to diagnosis of NMO (median 17 vs. 7 months, p < 0.05), higher comorbidities (66.7 vs. 26.7 %;
p < 0.05), and more hypertension (26.7 vs.3.3 %; p < 0.05) were prevalent. NMO-like lesions were less common (10.7 vs.
41.6 %; p < 0.05), while the rate of non-specific lesions tended to be higher (53.6 vs. 29 %; p = 0.067). These
patients displayed more severe Expanded Disability Status Scale (EDSS) in nadir (median 6.75vs.5; p < 0.05).
Attacks often resulted in EDSS 4 within a short period (median 8 vs. 13.5 months; p < 0.05). At last follow-up, the EDSS
score was more severe in these patients (median 5.25 vs. 4; p < 0.05). No significant predictors were identified.
Conclusions: This study provides an overview of the clinical and paraclinical features of AQP4-seropositive LONMOSD
patients in China and demonstrates a number of distinct disease characteristics in early vs. late onset. Older patients are
more susceptible to disability in short course. However, these patients do not always display NMO-like lesions in the brain.
Initial LETM may not necessarily be predominant as the initial symptom, contrary to previous reports. The higher
comorbidities may warrant a modified approach of treatment.
Background
Neuromyelitis optica (NMO) is an autoimmune inflam-
matory disease of the central nervous system (CNS)
characterized by recurrent episodes of optic neuritis (ON)
and longitudinally extensive transverse myelitis (LETM),
in which autoantibodies against AQP4 play an important
role [1–3]. In western countries, the disease mainly affects
adults aged between 30 and 40 years [4].However, recent
clinical studies suggest NMOSD in the elderly is not
uncommon, possibly partly due to improved diagnostic
methods in the aging population [5]. Multiple comorbidi-
ties may delay timely recognition of early symptoms of
NMO/NMOSD and accurate diagnosis in the elderly (e.g.
blurred vision may be attributed to macular degeneration).
Additionally, a high occurrence of elevated AQP4 anti-
body titer has been reported in elderly patients, suggesting
that there are even more unrecognized cases in this popu-
lation [6, 7]. Moreover, it is unclear whether the early- and
late-onset subgroups represent qualitatively distinct condi-
tions or differences along a quantitative dimension, such
as severity. The evolving epidemiology of NMO/NMOSD
with an increasing prevalence in the elderly calls into
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question whether there is a difference between early-onset
(EONMO/EONMOSD) and late-onset NMO/NMOSD
(LONMO/LONMOSD) phenotypes in patients who are
AQP4-seropositive, and warrants review as to whether a
different treatment approach is appropriate. Furthermore,
treatment decisions may be especially complicated in the
elderly, given the more likely presence of multiple co-
morbidities and subsequent iatrogenic complications
[8]. However, as far as we know, there have been few
studies into the potential differences between AQP4-
seropositive EONMO/NMOSD and LONMO/LON-
MOSD [9], and there is scarce epidemiological data
from developing countries. Additionally, older patients
tend to report decreased symptom severity in other auto-
immune disorders [10, 11]. However, this phenomenon
has not typically been supported in NMO studies [12].
Unfortunately, previous NMO studies have lacked ap-
propriate controls (e.g. early onset group) to test this
hypothesis [12]. Thus, there is inadequate conclusive
evidence to confirm the greater severity of AQP4-
seropositive NMO/NMOSD in late-onset patients.
In this study we report a detailed clinical analysis of 30
AQP4-seropositive NMO/LONMOSD patients ≥ 50 years
old (age at onset of first symptoms) and compare the
results with those of AQP4-seropositive EONMO/
EONMOSD patients (age at onset of first symptoms ≤
49 years), and we describe several novel features asso-
ciated with this age group.
Methods
Patient selection and assessment
Thirty consecutive late-onset AQP4-seropositive NMO
or NMOSD patients were identified from a clinical re-
view chart retrospectively between January2006 and
February2014. Among them, 23 AQP4-seropositive NMO
patients fulfilled the 2006 criteria [13], and 7 had either
isolated AQP4-seropositive ON or AQP4-seropositive
LETM [14]. For simplicity, we use the term NMOSD to
encompass both NMO and NMOSD. Seropositivity for
NMO-IgG was detected with an anti-AQP4 antibody
assay on an anti-AQP4 transfected cell line from a com-
mercial Biochip kit (Euroimmun, Lubeck, Germany) [15].
All patients tested positive for AQP4 antibodies at their
earliest available sample. All patients must have had one
or more follow-up visits at our center more than one year
after the onset of symptoms. These patients were assessed
by three neurologists in our multiple sclerosis (MS)
clinic (XH, WQ and ZL).Clinical information was ob-
tained by the authors or referring physicians at the
acute stage of the disease. Follow-up information was
obtained at regular intervals after symptom onset. Tele-
phone interviews were typically used if the patients had
been asymptomatic for years.
Data for missed study visits were obtainedby review of
all available medical records. The Expanded Disability
Status Scale (EDSS) scoring system was used to estimate
disability during and after the onset episode, at the time
of the first documented neurological examination, and at
each visit [16]. The nadir EDSS score was determined as
the maximum points during the acute episodes.
Patients who developed AQP4-seropositive NMOSD
at an age ≥ 50 years (age at onset of first symptoms) were
classified as those with LONMOSD and were considered
cases. Early-onset patients (age at onset of first symp-
toms ≤ 49 years), matched for sex and disease duration,
were randomly chosen for each case and were consid-
ered controls (or patients with EONMOSD). The cutoff
age for early- verse late-onset AQP4-seropositive NMOSD
was established based on previously published literature
[12], and similar thresholds have been used in other auto-
immune disorders, such as myasthenia gravis [10].
We collected the following variables: demographic, clin-
ical, neuroimaging and cerebrospinal fluid (CSF) findings.
Clinical variables included follow-up time (period from
enrollment to last visit), total disease duration (the time
elapsing from the date that the patient initially complained
of symptoms of NMOSD up to the point of last visit), and
comorbidities. Symptoms that occurred within one month
after the initial symptoms of relapse were considered part
of the same episode. Methylprednisolone administered
intravenously was prescribed in the acute stage, and some
patients received azathioprine or tacrolimus in the remis-
sion stage.
Other autoimmunity included coexisting autoimmune
disorders with or without autoantibodies and/or a posi-
tive test for antibodies. Comorbidities included: arterial
thrombotic events, venous thrombotic events, diabetes
mellitus (DM; either self-reported and/or physician-based
diagnosis and/or requiring pharmacologic treatment),
hypertension, and osteoporosis.
MRI scans of brain lesions were classified as (1) normal;
(2) nonspecific, described as a small number of white mat-
ter lesions with no MS features; (3) MS-like, lesions in
regions considered typical of MS (e.g. periventricular, jux-
tacortical, callosal, and infratentorial); and (4) NMO-like,
when lesions surrounded the fourth ventricle, hypothal-
amus, or aqueduct, with or without small deep white mat-
ter lesions [17, 18]. Spinal cord MRI scans were evaluated
for lesion length. The length of the spinal cord lesions
were expressed in terms of the number of vertebral seg-
ments. Laboratory tests of CSF included oligoclonal band-
ing, cell counts, and protein concentrations.
Ethical standard
This research was approved by the ethics committee of
the Third Affiliated Hospital of Sun Yat-Sen University.
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All participants involved in this study provided written
informed consent.
Statistical analysis
All statistical analyses were performed using Statistical
Program for Social Sciences (SPSS) statistical software
(version 17.0; Chicago, IL, USA). Categorical variables were
compared using Fisher’s exact test. Non-categorical vari-
ables were compared using the Mann–Whitney U test. Sur-
vival was estimated according to the Kaplan-Meier method.
The log-rank test was used to compare the survival analysis
between AQP4-seropositiveLO- and EONMOSD patients.
Factors influencing outcomes were assessed independently
by univariate binary logistic regressions (poor outcome
defined as EDSS ≥ 4). Factors associated with a poor out-
come were included in conditioned linear logistic analysis
with binary distribution. Two-sided p values < 0.05 were
considered significant.
Results
We identified thirty AQP4-seropositive LONMOSD pa-
tients (Table 1). The median age at onset was 57.5 years
(range 50–70), and 26 were female (86.7 %), similar to
the early onset group (90 %). Attack onset occurred with
similar frequencies between ON and LETM. Compared
with AQP4-seropositive EONMOSD, interval between
(first) ON and LETM and time from first symptoms to
diagnosis of NMO were longer in the late-onset group
(median 13 vs. 4 months, p < 0.05; median 17 vs.
7 months, p < 0.05). A higher proportion of comorbidi-
ties were displayed (66.7 vs. 26.7 %; p < 0.05), in which
hypertension was displayed most frequently (26.7 vs. 3.3
%; p < 0.05). Other comorbidity-related variables were
also observed in a higher proportion in late onset pa-
tients, although no significant differences were found.
NMO-like lesions in the brain were observed less fre-
quently (10.7 vs. 41.6 %; p < 0.05) in late-onset patients
(Table 2). More non-specific lesions (53.6 vs. 29 %;
p = 0.067) were also noted in this group, although no
significant difference was found. No significant differences
between groups were found in onset episode, monophasic
form, first inter-attack interval, total attacks, ARR, coexist-
ing autoimmunity, immunosuppressors, number of spinal
cord MRI or cerebrospinal fluid results.
Compared with AQP4-seropositive EONMOSD, the
severe EDSS scores in nadir (6.75 vs. 5; p < 0.05) were
higher in the late-onset group. The median time to
EDSS 4 in AQP4-positive LONMOSD was significantly
less than in AQP4-positive EONMOSD (8 vs. 13.5 months;
p < 0.05), as illustrated in Fig. 1. At the end of the follow-
up, the EDSS score was more severe (median 5.25 vs. 4;
p < 0.05) in the late-onset group compared with the
early-onset group. Only one patient from the late-onset
group died soon after hospitalization during the third
attack. Death in this patient was secondary to extensive
myelitis with pulmonary infection and respiratory fail-
ure. Finally, no significant prognostic factors were iden-
tified using univariate binary logistic regression; thus,
conditioned linear logistic analysis was not performed.
Discussion
Although the influences of differences in onset age in
NMOSD have been documented in a number of previ-
ous reports, there are no systematic studies comparing
late-onset to early-onset AQP4-seropositive NMOSD.
This study showed that AQP4-seropositive LONMOSD
was often characterized by severe attacks and resulted
in disability within a shorter time, compared with
AQP4-seropositive EONMOSD. Generally, our results
do not support the hypothesis that patients with
AQP4-seropositive LONMOSD show lower symptom
severity, as has been reported in other autoimmune dis-
orders [10, 11]. We also identified a number of distinct
disease characteristics assumed to be age-related, such
as longer interval between ON and LETM and time
from first symptoms to diagnosis, more concurrent
commodities, less NMO-like lesions and higher tenden-
cies towards non-specific lesions. Finally, this study
suggested that initial LETM may not necessarily be pre-
dominant among symptoms, as has been previously
reported [6, 9, 12].
In our study, late-onset patients were particularly severe,
with a higher disability rating after follow-up, in line with
previous Caucasian and Japanese cohorts [6, 12]. However,
the conclusions from the previous Caucasian study were
limited by failing to set an early-onset control and by
including AQP4-seronegative patients [12]. The creation
of a Japanese cohort was an attempt to compare different
clinical characteristics at different ages in AQP4-positive
NMOSD patients; however, this comparison only occurred
in a subanalysis, and therefore, a mere two difference vari-
ables (gender, lesion of first attack) were discussed [6]. In
contrast to the study of the Japanese cohort, in which no
information was given about total disease duration for
either type of case (late onset) or controls (early onset), we
matched our cases and controls for disease duration, which
makes our observations even stronger.
It is reasonable that older patients are more suscep-
tible to disability. During aging, there is a substantial
decline in the ability to resist immune and inflammatory
responses and a corresponding decline in the generation
of robust protective immune responses, leading to a
deficient anti-inflammatory process [19, 20]. It is also
possible that late-onset patients show a less positive
response to immunosuppressive therapy and experience
more side effects and, at the same time, present with
more frequent and severe comorbidities. Unfortunately,
no significant prognostic factors were identified in the
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univariate analysis. This difficulty in identifying prognos-
tic factors also occurred in a previous study [21]. Very
few prognostic factors for poor outcomes have been
identified in similar studies; among the few that have, a
later onset age seems to be the most important variable
[9, 12]. These scarce prognostic findings may partly reflect
the different treatments, responses and unpredictable
courses inherent in the disease, and it should be a call to
the NMO community to establish a better cooperation
model for the treatment of this late onset group.
Interestingly, we found longer interval between ON
and LETM in late-onset patients, which has not been
Table 1 Comparison of clinical features in patients with late-onset and early-onset AQP4-seropositive NMO/NMOSD
Feature Late-onset AQP4-Ab Positive (n = 30) Early-onset AQP4-Ab Positive (n = 30) p-value
Total disease duration, months 24 (13–120) 25.5 (13–122) 0.958
Follow-up, median, mo 16 (12–84) 19 (12–88) 0.45
Female 26 (86.7) 27 (90) 0.5
Age at onset, median, y 57.5 (50–70) 31 (13–49) <0.001
Onset episode, No.
ON only 13 (43.3) 13 (43.3) 0.603
TM only 15 (50) 13 (43.3) 0.398
ON + TM 1 (3) 3 (10) 0.306
Brain/brainstem 0 0 -
Mixed e.g. ON + brain 1 (3) 1 (3) 0.754
Median first interattack interval, months 7.5 (1–34) 6 (0.5–56) 0.58
Median interval between first ON and
LETM, months
13 (0–51) 4 (0–54) 0.022
Median time from first symptoms to
diagnosis of NMO
17 (0.5–52) 7 (0.5–54) 0.009
Monophasic 2 (6.6) 2 (6.6) 0.694
Total n of attacks 2.5 (1–11) 3 (1–7) 0.571
ARR 1.37 (0.5–2.9) 1.50 (0.5–2.99) 0.398
Coexisting autoimmunity, No. 11 (36.7) 7 (23.3) 0.20
Coexisting autoimmune disordersa 4 2 0.57
Autoantibodies (number of positive
tested/number tested)
7 5 0.57
Comorbidities, No. 20 (66.7) 8 (26.7) 0.002
Arterial thrombotic events 1 (3) 0 (0) 0.5
Venous thrombotic events 2 (6.7) 1 (3) 0.5
Diabetes mellitus 5 (16.7) 3 (10) 0.35
Hypertension 8 (26.7) 1 (3) 0.01
Osteoporosis 5 (16.7) 2 (6.6) 0.21
bImmunosuppressors 27 (90) 28 (93.3) 0.5
Corticosteroids 13 16 0.35
Azathioprine + corticosteroids 12 9 0.25
Tacrolimus + corticosteroids 2 3 0.52
Nadir EDSS score 6.75 (3–8.5) 5 (3–8) 0.007
Time to EDSS 4 8 (0–39) 13.5 (0–54) 0.026
EDSS score at last visit 5.25 (1.5–10) 4 (0.5–7.5) 0.002
Values are presented as frequencies (percentages) and medians (minimum-maximum)
ON optic neuritis, LETM longitudinally extensive transverse myelitis, ARR annualized relapse rate, EDSS Expanded Disability Status Scale
aCoexisting autoimmune disorders with or without autoantibodies included: Late-onset AQP4-Ab positive group: Sjögren syndrome (3 cases), Rheumatoid arthritis
(1 case); early-onset AQP4-Ab positive group: Sjögren syndrome (1 case), Graves’ disease (1 case)
bAutoantibodies (number of positive tested/number tested) included: Late-onset AQP4-Ab Positive group: anti-deoxyribo-nuclease B antibody (1 case), anti-nuclear
antibody (2 cases), anti-histone antibody (2 cases), anti-keratin antibody (1 case), anti-cyclic citrullinated peptide antibody (1 case); Early-onset AQP4-Ab Positive
group: anti-double-stranded DNA antibody (1 case), anti-nuclear antibody (2 cases), anti-histone antibody (2 cases)
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reported before. This observation may reveal differential
age-dependent anatomical susceptibilities or age-related
decreased susceptibility to AQP4 antibody accessibility
from one target organ to another organ (ON to LETM,
vice versa). Considering the severity of the pathology in
each anatomical attack, the delay interval between ON
and LETM emphasizes the importance of identifying
early predictive factors for developing NMO from NMOSD
in future research. Additionally, we observed that the time
from first symptoms to diagnosis of NMO was longer than
early-onset. This may partly be due to longer interval
between ON and LETM per se. However, the possibility of
an unusual presentation of late-onset patients must be kept
in mind. For example, some AQP4-positive LONMOSD
Fig. 1 Time to the assignment of Expanded Disability Status Scale 4 in AQP4-positive neuromyelitis optica spectrum disorder patients with early-onset
vs. late-onset
Table 2 MRI and CSF findings in patients with late-onset and early-onset AQP4-seropositive NMO/NMOSD
Feature Late-onset AQP4-Ab Positive Early-onset AQP4-Ab Positive p value
Brain MRI, n 28 (93.3) 24 (80)
Normal 4 (14.3) 5 (21) 0.398
Nonspecific 15 (53.6) 7 (29) 0.067
MS-like 1 (3.6) 3 (12.5) 0.249
NMO-like 3 (10.7) 10 (41.6) 0.012
Spinal cord MRI, n 28 (93.3) 27 (90)
Length of spinal lesion, VBs, median 6 (3–16) 5 (0–19) 0.914
CSF analysis
CSF pleocytosis, WBC count ≥10/μL, n/total 5/24 (20.8) 6/24 (25) 0.5
Elevated CSF protein, >0.6 g/L, n/total 4/24 (16.7) 3/24 (12.5) 0.45
Oligoclonal bands positivity, n/total 1/20 (5) 2/20 (10) 0.46
Values are represented as frequencies (percentages; % of those examined) and medians (minimum–maximum)
MS multiple sclerosis, NMO neuromyelitis optica, VB vertebral body, CSF cerebrospinal fluid, WBC white blood cells
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patients presented a clinical picture complicated by other
commodities, higher tendencies towards non-specific le-
sions, and fewer classic brain lesions manifestations. This
may tend to result in diagnostic delay.
Unlike previous reports indicating a predominance of
LETM in NMOSD [6, 9, 12], we did not detect significant
exhibition of LETM as the initial symptom in late-onset
patients. Notably, our study cannot be directly compared
with previous results, such as the Caucasian study de-
scribe above [12]. In fact, the frequency of exhibition of
LETM in late-onset AQP4-seropositive patients was not
conspicuous (44.4 %) in the Caucasian study, according to
their subgroup analysis [12]. Additionally, the conclusions
in previous studies that higher rates of myelitis observed
in the UK and Japan were somewhat limited by failing to
include an ethnically homogeneous population [9]. In an-
other Japanese cohort, the chosen threshold cutoff age
(60 years) differed from the cut-offs used in (other) NMO,
multiple sclerosis and autoimmune disease research [6].
Another explanation for these differing symptom reports
could be due to different AQP4-Abs tests and incomplete
case ascertainment (e.g. a patient with minor ON may not
be willing to participate in an AQP4-Abs test). Hence, the
frequency of AQP4-seropositiveON could have been
underestimated in some areas. This will tend to lead to
higher frequencies of initial myelitis when calculating the
proportion of initial symptom in NMOSD. Additionally,
ethnic influence should still be considered as a potential
explanation for this difference. A population-based study
may improve conclusions about the prevalence of initial
myelitis in these patients.
Concurrent underlying comorbidities increase the risk
of complications in the elderly. Accordingly, this will
require consideration of a wide differential diagnosis. As
expected, hypertension was more frequent among late-
onset patients, either alone or in addition to a higher
prevalence of other comorbidities (Table 1). These pro-
cesses are likely to be age related rather than NMOSD
related, but they likely exert an additive or even a syner-
gistic effect on morbidity and disability. Furthermore,
the management of AQP4-seropositive LONMOSD is
complicated by more common occurrence of DM and
osteoporosis in these patients, limiting the use of cor-
ticosteroid treatment.
Our results revealed a high frequency of brain lesions
(sum of non-specific, MS-like, and NMO-like), in line
with previous reports [5, 6, 12]. However, unlike early-
onset patients, we found that these NMO-like lesions
were less often in AQP4-seropositive LONMOSD. This
result may be a reflection of the intensity of the inflam-
matory process or a high level of autoimmune activity in
early-onset patients (as opposed to late onset). Further-
more, we noted a tendency towards more frequent, non-
specific lesions in AQP4-seropositive LONMOSD, partly
reflecting the influence of these age-related comorbidi-
ties (e.g. heavier atherosclerotic burden). Taken together,
these mixed neuroimaging characteristics of NMOSD
may pose a greater challenge for differential diagnosis.
Our study had some limitations. First, owing to the
retrospective design of this study, selection bias may have
limited the interpretation of our results. The predominant
recruitment of patients in our center may have led to
benign types of patients being underrepresented, because
potential mild types may fail to reach hospital attention.
The detailed analysis of comorbidities and treatment
effects in this study was also limited by its retrospective
nature. Second, the low proportion of deaths compared
with other studies may have been due to selection bias or
to the relatively short follow-up period in our study
(median 16 and 19 months in each group), limiting
its interpretation. Third, our cohort could not use the up-
dated version of diagnostic criteria for AQP4-seropositive
LONMOSD, which was published recently, due to the
earlier performance of this study [22]. However, we
emphasized that this proposed diagnostic criteria is appro-
priate for our patients, whose diagnoses were based on the
classic ON and/or LETM involvement, positive results of
AQP4-IgG, and exclusion of alternative diagnoses at a
center with well-established expertise in the NMOSD.
Last but not least, we did not observe the first onset with
more extensive CNS involvement compatible to the
revised criteria other than ON and/or LETM involvement,
for example, area postrema, other brainstem, dienceph-
alon, or cerebra [22]. Although these unreported results
may partly reflect the disease state of LONMOSD itself, it
is also possible that future larger studies will led to recog-
nition of more extensive manifestations using the revised
criteria [22, 23].
Despite these limitations, our data extends our know-
ledge of the clinical, diagnostic and prognostic impacts
of this rare yet often devastating condition. Our study
also provides some explanation for the possible differ-
ences in NMOSD between younger and older onset
cases and indicates some are related to NMOSD, and
some are not related to NMOSD (e.g. comorbidities).
Conclusion and implication
This study provides an overview of the clinical and para-
clinical features of AQP4-seropositive LONMOSD pa-
tients in China and demonstrates a number of distinct
disease characteristics in early vs. late onset. Our find-
ings have several implications. In patients ≥50 years old,
AQP4-seropositive NMOSD is dominant in females and
occurs with similar frequencies and onset episodes; how-
ever, older patients are more susceptible to disability.
Diagnoses delay may occur more frequently and diagno-
ses should be made with a wider differentialdiagnosis
space due to a number of novel distinct disease
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characteristics in late onset, such as fewer NMO-like le-
sions in the presence of more non-specific lesions and
more concurrent commodities. The higher burden of
comorbidities may warrant a modified approach of
treatment. Because there are no reliable prognostic bio-
markers in AQP4-seropositive LONMOSD currently, it
is difficult to predict outcomes or clinical courses at any
stage in this group. Therefore, attack-prevention therap-
ies should be initiated as early as possible, regardless of
the initial presentation, course of disease, or degree of
disability at the time of diagnosis.
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